Researchers have developed a blood test able to detect more than 50 types of cancer that is accurate enough to be used nationally as a multi-cancer screening test in those at higher risk of the disease, including those aged over 50 with no symptoms.

The test involves taking a sample of blood from each patient and analysing it for DNA, known as cell-free DNA (cfDNA), shed by tumours (and other cells) into the blood. Genomic sequencing is used to detect chemical changes to the DNA (methylation) that control gene expression, and a classifier developed with machine learning (artificial intelligence) uses these results to detect abnormal methylation patterns that indicate the presence of cancer.

The third and final sub-study of the Circulating Cell-free Genome Atlas (CCGA) study, published in the Annals of Oncology, investigated the performance of the test in 2,823 people already diagnosed with cancer and 1,254 people without cancer.

The findings show that the test was able to detect cancer signals from more than 50 different types of cancer across all four cancer stages (I, II, III, IV), correctly identifying when cancer was present in 51.5% of cases. The test’s specificity was 99.5%, thus showing that it wrongly detected cancer in just 0.5% of cases.

According to the data, sensitivity of the test was 67.6% overall across stages I-III in 12 pre-specified cancers that account for two-thirds of cancer deaths in the US annually (anal, bladder, bowel, oesophageal, stomach, head and neck, liver and bile duct, lung, ovarian and pancreatic cancers, lymphoma and cancers of white blood cells such as multiple myeloma), and 40.7% overall in more than 50 cancers.

For all cancers, detection improved with each later cancer stage with a sensitivity rate of 16.8% at the early stage I, 40.4% at stage II, 77% at stage III and 90.1% at stage IV.

Research also showed that sensitivity varied by type of cancer; in solid tumours that do not have any screening options – such as oesophageal, liver and pancreatic cancers – overall sensitivity of the test was twice that for solid tumours that do have screening options, such as breast, bowel, cervical and prostate cancers: 65.6% compared to 33.7%. Overall sensitivity in cancers of the blood, such as lymphoma and myeloma, was 55.1%.

The test correctly also identified the tissue in which the cancer was located in the body in 88.7% of cases, the researchers said.

“These data add to a growing body of literature that supports the use of next-generation sequencing for the detection of cell-free DNA in blood samples as a tool for earlier detection of common cancers that account for a significant number of deaths and other health problems worldwide,” said first author of the paper, Dr Eric Klein, chairman of the Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, US.

“In addition, a screening test that requires only a simple blood draw could provide an option for communities that have poor access to medical facilities. I’m excited about the potential impact this approach will have on public health.”

Reference:
https://www.pharmatimes.com/news/blood_test_can_detect_more_than_50_types_of_cancer_1372224

More News
NEW DRUGS (AMENDMENT) RULES,2022 MANDATES QR CODES FOR ACTIVE PHARMACEUTICAL INGREDIENTS
News · 01/07/2022

The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.

READ MORE
European Green Deal
News · 01/07/2022

On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.

READ MORE
Neoadjuvant Dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer
News · 01/07/2022

According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.

READ MORE
Global recession? Not yet…
News · 02/06/2022

As the war in Ukraine and pandemic disruptions continue to wreak havoc on supply chains, stagflation is here to stay – marked by low growth and high inflation for at least the next 12 months.

The pandemic as well as the war in Ukraine have stifled supply of commodities and goods and upended efficient distribution through global supply chains, forcing up prices of everyday goods such as fuel and food.

READ MORE
Roche develops unique PCR tests to detect the monkeypox virus
News · 01/06/2022

Roche and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns. Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.

READ MORE
Containers pile up in Shanghai port on China’s COVID lockdowns
News · 02/05/2022

The strictest COVID -19 lockdown in China since the pandemic began has resulted in container goods sitting at Shanghai’s port for nearly two weeks.

READ MORE
Could cyber-physical watermarks be the key to pill-level traceability?
News · 01/04/2022

New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.

READ MORE
World economy faces supply hit as China battles Covid
News · 01/04/2022

The global economy — already struggling with war in Ukraine and the stagflation risks it’s fanning — is bracing for greater disruption as China scrambles to contain its worst outbreak of Covid-19 since the pandemic began.

READ MORE
Impact of Oil hitting a seven-year high on world economy
News · 02/03/2022

Oil prices surged past $100 (£74) a barrel to hit their highest level for more than seven years after Russia launched an invasion of Ukraine.

READ MORE